Skip to content

Study · Randomized controlled trial · n = 34 · 2021

4 results

GLP1 Receptor Agonists Reduce Fluid Intake in Primary Polydipsia

Winzeler B, Sailer C, Coynel D, Deborah V, Davide Z, Urwyler S, Refardt J, Christ-Crain M

Journal of the Endocrine Society3 May 2021

PMCIDPMC8090681 (opens in a new tab)PepBankPUB-99089389
Read at sourceSource pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, dulaglutide reduced fluid intake versus placebo.

    In plain wordsIn patients with excessive drinking, dulaglutide reduced fluid intake compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTotal fluid intake
    Study

    n = 34

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Appetite and food intake · Kidney and urinary
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Measurements

    Median fluid intake
    2250 ml
    dulaglutide
    Median fluid intake
    2400 ml
    placebo
    Fluid intake difference
    −490 ml
    versus placebo
    Relative reduction
    17%
    versus placebo

    Source sentences

    Summary
    Results Median [IQR] total fluid intake was 2250ml [1600-2600] on dulaglutide versus 2400ml [1850-3400] on placebo.
    3 context sentences
    Summary · context
    Patients on dulaglutide reduced fluid intake by 490ml [95%-CI -780, -199], p=0.002, corresponding to a relative reduction of 17%.
    Summary · context
    The primary endpoint was total fluid intake during the evaluation visits.
    Summary · context
    In this randomized, double-blind, placebo-controlled, 3-week crossover-trial, 34 patients with primary polydipsia received weekly dulaglutide (Trulicity®) 1.5mg and placebo (0.9% sodium chloride).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, dulaglutide reduced urinary output versus placebo.

    In plain wordsIn patients with excessive drinking, dulaglutide reduced urine output compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Decrease24-hour urinary output
    Study

    n = 34

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Measurements

    Urinary output difference
    −943 ml
    versus placebo

    Source sentences

    Summary
    24-hour urinary output was reduced by -943ml [95%-CI -1473, -413].
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 3-week crossover-trial, 34 patients with primary polydipsia received weekly dulaglutide (Trulicity®) 1.5mg and placebo (0.9% sodium chloride).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, dulaglutide reduced thirst responses to beverage pictures versus placebo.

    In plain wordsIn patients with excessive drinking, dulaglutide reduced thirst during beverage pictures compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseThirst response to beverage pictures
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Thirst perception in response to beverage pictures was higher in patients with primary polydipsia versus controls and lower on dulaglutide versus placebo, but functional neuronal activity was similar between groups and treatments.
    2 context sentences
    Summary · context
    In a subset of 15 patients and matched controls, thirst perception and neuronal activity in response to beverage pictures were assessed by functional MRI.
    Summary · context
    In this randomized, double-blind, placebo-controlled, 3-week crossover-trial, 34 patients with primary polydipsia received weekly dulaglutide (Trulicity®) 1.5mg and placebo (0.9% sodium chloride).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, functional neuronal activity was similar during dulaglutide and placebo treatment.

    In plain wordsIn patients with excessive drinking, brain activity was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedFunctional neuronal activity
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Thirst perception in response to beverage pictures was higher in patients with primary polydipsia versus controls and lower on dulaglutide versus placebo, but functional neuronal activity was similar between groups and treatments.
    2 context sentences
    Summary · context
    In a subset of 15 patients and matched controls, thirst perception and neuronal activity in response to beverage pictures were assessed by functional MRI.
    Summary · context
    In this randomized, double-blind, placebo-controlled, 3-week crossover-trial, 34 patients with primary polydipsia received weekly dulaglutide (Trulicity®) 1.5mg and placebo (0.9% sodium chloride).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.